Developing a novel class of complete microbiota ecosystem products and
microbiome therapies to address unmet challenges in human diseases.

Our preclinical stage programs and related information are disclosed below:

Program Indication Product Type(s) Discovery Preclinical Clinical
MVT-201 Infectious Diseases Complete Microbiota HPM®    
MVT-2401 Oncology Bacterial consortia & HPM®  

Program: MVT-201

Indication:Infectious Diseases

Product Type(s): Complete Microbiota HPM®

Preclinical Fase

Program: MVT-2401


Product Type(s): Bacterial consortia & HPM®

Discovery fase

Over the last years we have built our platform powered by innovation leading to tangible products and services already marketed.

We are currently focused on developing novel biotherapeutics based on complete microbiota ecosystem products that are at preclinical stage for various medical applications. Additionally, we have a large and diverse bacterial strain collection for the development of novel LBPs and probiotics to cover the patients’ needs.


We have entered into a translational clinical collaboration with Inmunomet Intolerancias y Disbiosis to develop novel microbiome therapies as precision medicine . Inmunomet is a private medical group with extensive experience in gut associated disorders and it became Microviable’s lead investor after the 1.5M seed funding in 2022.

We have entered into a research collaboration with the University Medical Center of Utrecht focused on understanding the gut microbiota implications in the success and side effects of immune checkpoint inhibition (ICI) therapies for cancer treatments.

We have entered into a translational research collaboration with Hospital Ramón y Cajal focused on microbiome-derived therapeutic applications for multi-drug resistant infections.